Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease

Pediatric Blood and Cancer

Volumn 60, Issue 4, 2013, Pages 653-658

  Oyeku, Suzette O ^a   Driscoll, M Catherine ^a   Cohen, Hillel W ^a   Trachtman, Rebecca ^a   Pashankar, Farzana ^b   Mullen, Craig ^c   Giardina, Patricia J ^d   Velazco, Nerissa ^a   Racine, Andrew D ^a   Green, Nancy S ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Department of Medicine   (United States)

Author keywords

Barriers; Hydroxyurea; Knowledge; Outcomes research; Sickle cell disease

Indexed keywords

ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; HYDROXYUREA;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; AWARENESS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HEALTH SURVEY; HUMAN; INSTITUTIONAL CARE; KNOWLEDGE; LONG TERM CARE; MALE; OFF LABEL DRUG USE; PAIN; PARENT; PARENTAL ATTITUDE; PHYSICIAN; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; UTILIZATION REVIEW;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYUREA; MALE; PARENTS;

EID: 84873732466     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24381     Document Type: Article

References (27)

1. National Institutes of Health. National Heart, Lung and Blood Disease Institute and Division of Blood Diseases and Resources. The management of sickle cell disease. NIH Publication (No. 02-2117), 4th edition. Bethesda, MD; 2002.
2. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
3. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality, morbidity in adult sickle cell anemia: Risks, benefits up to 9 years of treatment [erratum appears in JAMA, 2003 Aug 13;290(6):756]. JAMA 2003; 289: 1645-1651.
4. Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol 2011; 33: 251-254.
5. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opin Hematol 2011; 18: 158-165.
6. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86: 273-277.
7. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377: 1663-1672.
8. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94: 1550-1554.
9. Hoppe C, Vichinsky E, Quirolo K, et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 2000; 22: 330-334.
10. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103: 2039-2045.
11. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 2010; 24: 199-214.
12. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115: 5300-5311.
13. National Institutes of Health, National Heart, Lung and Blood Institute. Draft recommendations on the use of hydroxyurea therapy in sickle cell disease; November 17, 2010.
14. Tripathi A, Jerrell JM, Stallworth JR. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Pediatr Blood Cancer 2011; 56: 90-94.
15. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932-938.
16. Chlebowy DO, Hood S, LaJoie AS. Facilitators and barriers to self-management of type 2 diabetes among urban African American adults: Focus group findings. Diabetes Educ 36: 897-905.
17. Bogart LM, Wagner G, Galvan FH, et al. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among African American men with HIV. J Acquir Immune Defic Syndr 53: 648-655.
18. Saha S, Jacobs EA, Moore RD, et al. Trust in physicians and racial disparities in HIV care. AIDS Patient Care STDS 24: 415-420.
19. Ogedegbe G, Harrison M, Robbins L, et al. Barriers and facilitators of medication adherence in hypertensive African Americans: A qualitative study. Ethn Dis 2004; 14: 3-12.
20. Champion VL, Springston J. Mammography adherence and beliefs in a sample of low-income African American women. Int J Behav Med 1999; 6: 228-240.
21. Haywood C, Jr., Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol 2011; 86: 85-87.
22. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep) 2008; 1-95.
23. Lanzkron S, Haywood C, Jr., Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: A survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc 2008; 100: 968-973.
24. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: A survey of Florida and North Carolina hematologists/oncologists. Am J Hematol 2005; 79: 107-113.
25. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. Am J Hematol 2010; 85: 611-613.
26. Sobota A, Graham DA, Heeney MM, et al. Corticosteroids for acute chest syndrome in children with sickle cell disease: Variation in use and association with length of stay and readmission. Am J Hematol 2010; 85: 24-28.
27. Sobota A, Graham DA, Neufeld EJ, et al. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: Risk factors and hospital variation. Pediatr Blood Cancer 2012; 58: 61-65.